| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $1,224,096 | 9 | 100 |
Sells | $0 | 0 | 0 |
| COLLIS STEVEN H | director | 1 | $267,150 | 0 | $0 | $267,150 |
| SAUNDERS BRENT L | CEO and Chairman of the Board | 1 | $251,958 | 0 | $0 | $251,958 |
| Bailey A Robert D | EVP & Chief Legal Officer | 1 | $250,332 | 0 | $0 | $250,332 |
| VON ESCHENBACH ANDREW C. | director | 1 | $79,883 | 0 | $0 | $79,883 |
| Ross Thomas W. Sr. | director | 1 | $79,556 | 0 | $0 | $79,556 |
| ROBERTSON RUSSEL C | director | 1 | $78,760 | 0 | $0 | $78,760 |
| Alfonso Eduardo | director | 1 | $76,970 | 0 | $0 | $76,970 |
| Ling Karen | director | 1 | $70,968 | 0 | $0 | $70,968 |
| Eldessouky Sam | EVP and CFO | 1 | $68,520 | 0 | $0 | $68,520 |
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Over the last 12 months, insiders at Bausch + Lomb Corporation have bought $1.22M and sold $0 worth of Bausch + Lomb Corporation stock.
On average, over the past 5 years, insiders at Bausch + Lomb Corporation have bought $998,580 and sold $1.35B worth of stock each year.
Highest buying activity among insiders over the last 12 months: COLLIS STEVEN H (director) — $267,150. SAUNDERS BRENT L (CEO and Chairman of the Board) — $251,958. Bailey A Robert D (EVP & Chief Legal Officer) — $250,332.
The last purchase of 14,700 shares for transaction amount of $251,958 was made by SAUNDERS BRENT L (CEO and Chairman of the Board) on 2026‑03‑06.
| 2026-03-06 | SAUNDERS BRENT L | CEO and Chairman of the Board | 14,700 0.0042% | $17.14 | $251,958 | -6.04% | ||
| 2026-03-06 | Eldessouky Sam | EVP and CFO | 4,000 0.0011% | $17.13 | $68,520 | -6.04% | ||
| 2026-03-06 | Bailey A Robert D | EVP & Chief Legal Officer | 14,600 0.0041% | $17.15 | $250,332 | -6.04% | ||
| 2026-03-03 | Ross Thomas W. Sr. | director | 4,500 0.0012% | $17.68 | $79,556 | -10.76% | ||
| 2026-03-02 | Alfonso Eduardo | director | 4,300 0.0012% | $17.90 | $76,970 | -12.82% | ||
| 2026-02-27 | VON ESCHENBACH ANDREW C. | director | 4,364 0.0012% | $18.30 | $79,883 | -12.21% | ||
| 2026-02-23 | COLLIS STEVEN H | director | 15,000 0.0042% | $17.81 | $267,150 | -10.37% | ||
| 2026-02-20 | ROBERTSON RUSSEL C | director | 4,400 0.0012% | $17.90 | $78,760 | -10.09% | ||
| 2026-02-19 | Ling Karen | director | 4,000 0.0011% | $17.74 | $70,968 | -8.56% | ||
| 2025-05-22 | SAUNDERS BRENT L | CEO and Chairman of the Board | 22,000 0.0062% | $11.28 | $248,072 | +39.64% | ||
| 2025-05-02 | VON ESCHENBACH ANDREW C. | director | 1,695 0.0005% | $11.76 | $19,925 | +33.30% | ||
| 2024-08-05 | SAUNDERS BRENT L | CEO and Chairman of the Board | 32,250 0.0093% | $15.66 | $505,067 | +3.60% | ||
| 2022-06-01 | Sale | Bausch Health Companies Inc. | 9.1M 2.724% | $17.05 | $155.21M | -1.47% | ||
| 2022-05-10 | Sale | Bausch Health Companies Inc. | 70M 19.4359% | $17.05 | $1.19B | -8.60% |
| SAUNDERS BRENT L | CEO and Chairman of the Board | 966575 0.2711% | $14.94M | 3 | 0 | +3.6% |
| Eldessouky Sam | EVP and CFO | 403130 0.1131% | $6.23M | 1 | 0 | |
| Bailey A Robert D | EVP & Chief Legal Officer | 231890 0.065% | $3.59M | 1 | 0 | |
| ROBERTSON RUSSEL C | director | 72407 0.0203% | $1.12M | 1 | 0 | |
| VON ESCHENBACH ANDREW C. | director | 66450 0.0186% | $1.03M | 2 | 0 | +33.3% |
| Ross Thomas W. Sr. | director | 64891 0.0182% | $1M | 1 | 0 | |
| Ling Karen | director | 41676 0.0117% | $644,310.96 | 1 | 0 | |
| COLLIS STEVEN H | director | 20255 0.0057% | $313,142.30 | 1 | 0 | |
| Alfonso Eduardo | director | 9555 0.0027% | $147,720.30 | 1 | 0 | |
| Bausch Health Companies Inc. | 310449643 87.0738% | $4.8B | 0 | 2 |
$167,495 | 10 | 32.53% | $53.41M | |
$8,662,717 | 6 | -49.85% | $3.62M | |
$858,500 | 3 | 13.15% | $1.13B | |
$34,477,719 | 2 | -9.33% | $44.82M | |
Bausch + Lomb Corporation (BLCO) | $524,992 | 2 | 18.45% | $5.51B |
| Increased Positions | 51 | +45.54% | 5M | +12.42% |
| Decreased Positions | 46 | -41.07% | 4M | -10.96% |
| New Positions | 20 | New | 1M | New |
| Sold Out Positions | 14 | Sold Out | 3M | Sold Out |
| Total Postitions | 117 | +4.46% | 40M | +1.46% |
| Icahn Carl C | $58,030.00 | 0.99% | 3.5M | 0 | 0% | 2025-09-30 |
| Deutsche Bank Ag | $58,030.00 | 0.99% | 3.5M | +89,900 | +2.64% | 2025-09-30 |
| Oaktree Capital Management Lp | $53,809.00 | 0.92% | 3.25M | +724,194 | +28.72% | 2025-09-30 |
| Goldentree Asset Management Lp | $44,111.00 | 0.75% | 2.66M | +77,323 | +2.99% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $43,224.00 | 0.74% | 2.61M | 0 | 0% | 2025-09-30 |
| Silver Point Capital L.P. | $42,528.00 | 0.73% | 2.56M | +3M | New | 2025-09-30 |
| Fmr Llc | $25,867.00 | 0.44% | 1.56M | +788,291 | +102.13% | 2025-09-30 |
| Glenview Capital Management, Llc | $25,763.00 | 0.44% | 1.55M | 0 | 0% | 2025-09-30 |
| Nomura Holdings Inc | $20,827.00 | 0.36% | 1.26M | 0 | 0% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $20,509.00 | 0.35% | 1.24M | -12,347 | -0.99% | 2025-09-30 |